Roche claims lebrikizumab could be first personalised asthma treatment
This article was originally published in Scrip
Executive Summary
Roche's investigational humanised monoclonal antibody, lebrikizumab, has met the primary endpoint in a Phase II study, prompting the company to claim that the drug has potential to be the first personalised treatment for asthma.